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Background:  Ischemic  preconditioning  (IPC)  is  a powerful  mechanism  for  limiting  myocardial  infarction
during  or  after  ischemia–reperfusion  (IR) injury.  However,  effective  target  genes  and  proteins  for  IPC
are  unknown.  We  characterized  global  changes  in  gene  expression  in the  heart  during  IR, and  identiﬁed
effective  target  genes  for  IPC.
Methods:  Hearts  were  isolated  from  Sprague-Dawley  rats  under  control,  IR,  and IPC  conditions.  We  gen-
erated expressed-sequence-tags  (ESTs)  for each  group  and  investigated  their  functions  and  the  major
biological  processes  in  which  they  are  involved  using  the  eukaryotic  clusters  of orthologous  groups  (KOG)
database  and bioinformatics  analysis  tools.
Results: IR  modiﬁed  the expression  of 126  genes.  Of these,  62  were  upregulated,  64  were  downregulated,
and  77  were  found  to be  effective  target  genes  for IPC.  In KOG  analysis,  most  of  the  genes  whose  expression
was  modiﬁed  were  involved  in energy  production  and  conversion  and the  cytoskeleton.  A  gene-to-gene
interaction  map  revealed  that IR modiﬁed  the  expression  of  genes  in  four  major  functional  modules:
electron  transport  chain/oxidative  phosphorylation;  tricarboxylic  acid  cycle/glucose  metabolism/amino
acid  metabolism;  cellular  structure  and  contraction;  and  gene  transcription,  translation,  and  protein
folding.  At the  individual  gene  level,  the  genes  encoding  mitochondrial  cytochrome  c oxidase  subunits
2  and  3 were  downregulated,  and  those  encoding  the major  cytoskeleton  components  tropomyosin,
myosin  light  chain,  myomesin  2, and  myosin  regulatory  light chain  2, as  well  as the  gene  encoding  the
iron-storage  protein  ferritin,  were  upregulated,  and  thus  were  identiﬁed  as  potential  target  genes. Real
time PCR  evaluated  expression  patterns  of three  mitochondrial  IPC  effective  genes.  Two-dimensional
electrophoresis  proteomic  analyses  revealed  altered  expression  of  14  target  proteins.  The  expression
patterns  of  six  proteins  matched  the  corresponding  EST  expression  patterns.
Conclusion:  The  global  proﬁling  of cardiac  ischemia-related  genes  provides  the  possible  mechanisms  of
IR and  IPC  and  ways  of  treating  IR injury.
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Introduction
Cardiac ischemia and ischemia–reperfusion (IR) injury are major
contributors to morbidity and mortality worldwide [1].  Clinically,
discovery of early diagnosis markers of ischemic heart disease
and myocardial infarction, and pharmacological post-ischemic
treatments therapies (e.g. statins or ATP treatment) were widely
investigated for reducing infarction size and mortality after IR
injury [2–5]. Impairment of calcium balance and lipid homeo-
stasis, accelerated generation of reactive oxygen species, loss of
vier Ltd. All rights reserved.
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igh-energy phosphates, and the accumulation of harmful catabo-
ites are believed to play crucial roles in the pathogenesis of IR injury
6,7].
Ischemic preconditioning (IPC) is deﬁned as a short period of
yocardial IR that reduces subsequent lethal IR injury [8];  it is the
ost powerful mechanism known for limiting cardiac infarction
9]. During the past 20 years, much information about the signal-
ng pathways involved in preconditioning has been discovered and
as increased our understanding of the underlying mechanism [8].
n spite of the identiﬁcation of these signaling pathways, the pre-
ise mechanism by which these pathways reduce cell death is only
eginning to be understood [10]. Recently, genetic proﬁling of heart
nd heart disease models was performed to develop strategies
or enhancing beneﬁcial gene expression changes, and inhibiting
otentially harmful ones, during cardiac development [11], atrial
brillation [12], oxidative stress-induced cardiac myocyte apopto-
is [13], and ischemic preconditions [14]. Furthermore, large-scale,
peciﬁc, disease-targeted gene expression proﬁling analyses have
rovided a large amount of information as like a whole cDNA library
ith expressed sequence tags (ESTs) in heart and its speciﬁc state
15,16].  For example, Hwang et al. [15] suggested a new strategy
or developing cardiovascular medicine based on the generation
f 43,285 ESTs from human heart cDNA libraries related to hyper-
rophy genes, while Megy et al. [16] identiﬁed 35 heart-speciﬁc
enes from 4303 ESTs through the analysis of human EST start
ibraries. These studies demonstrated rapid and effective EST-based
pproaches for identifying genes expressed in the cardiovascular
ystem. Although the rat has been widely used to study cardio-
ascular physiology [17,18], a comprehensive set of rat cDNAs and
STs for analyzing genes related to ischemic heart disease is not yet
vailable.
In the present study, we integrated EST and proteomic
pproaches to analyze the expression of genes and proteins in rat
earts exposed to control conditions (Con), ischemia precondition-
ng (IPC), and ischemia/reperfusion (IR) to better understand how
PC treatment regulates gene and protein expression in ways that
ay  protect the heart from serious IR injury.
ethods
nimal cardiac ischemic model
Eight-week-old Sprague-Dawley rats were anesthetized with
odium pentobarbital (1 mg/kg) and heparin (300 IU/mL/kg).
welve isolated rat hearts were divided into three groups (Con, IR,
nd IPC groups; four per group), and perfused using a modiﬁed Lan-
endorff model with normal Tyrode’s (NT) solution and ischemic
olution as previously described (see Supplementary Materials for
ull details of the procedure) [19]. After treatment, two  hearts per
roup were subjected to EST analysis, and the other two were used
n proteomic analysis.
DNA library construction
Rat hearts from the three different groups were homogenized
n liquid nitrogen. Total RNA was isolated with TRIzol. Then mRNA
as puriﬁed from the total RNA using an mRNA puriﬁcation kit. A
DNA library was generated using a ZAP Express cDNA Synthesis
it (pBK-CMV vector; Stratagene, La Jolla, CA, USA). Brieﬂy, cDNA
as ligated into a TriplEx2 vector and packaged using the Giga-
ack Gold l packaging system (Stratagene). The library contained
.6 × 105 plaque-forming units (pfu). A total of 40 random plaques
ere chosen from each library for polymerase chain reaction (PCR)
mpliﬁcation and digested with the restriction enzyme SﬁI.  The
verage insert size was  determined through comparison with aiology 60 (2012) 98–110 99
standard 100-bp ladder after electrophoresis at 180 V on a 0.8%
agarose gel.
DNA sequencing
The lambda TripleEx2 vector (linear form) was  converted into
the pTriplEx2 vector (circular form) with Escherichia coli,  which
utilizes the Cre-loxP recombination system. Plasmid DNA isolated
by the standard alkaline lysis method was  ampliﬁed by the dye-
terminator cycling method using a BigDye® Terminator v3.1 Cycle
Sequencing Kit and 5′ universal primers in the vector (Stratagene),
and was sequenced using an ABI3730 XL capillary sequencer.
Sequence analysis
The chromatogram ﬁles obtained from the sequencer were
initially submitted to Phred [20,21] for base calling and qual-
ity assignment. The trace ﬁles were trimmed with trim-alt 0.05
and sequences shorter than 100 bp were removed. In addi-
tion, vector trimming was conducted with cross match software
(http://www.phrap.org), and poly-A sequences were removed
using the trimest function in the Emboss package [22]. The prepared
MultiFASTA format data were clustered and assembled using TIGR
gene indices clustering tools [23]. Finally, the contigs and single-
tons were analyzed using NCBI local BLAST [24]. Sequences were
searched against the NCBI nr database. Matches with E-values of
1e−10 for BLASTx were considered putative hits.
Functional annotation and associated network analysis
Identiﬁed ESTs were primarily categorized and anno-
tated using the eukaryotic clusters of orthologous groups
(KOG) algorithm for complete genomes (http://www.ncbi.nlm.
nih.gov/COG/grace/shokog.cgi). Gene interactions and functional
associations between identiﬁed genes were analyzed using the
online search tool for the retrieval of interacting genes/proteins
(STRING) 8.0 database (http://string.embl.de)  and were rearranged
using a network analysis and visualization program (cytoscape
2.6.2) [25]. Protein subcellular localization and functional anno-
tation were analyzed using the proteome analyst specialized
subcellular localization server v.2.5 [26] and the protein analy-
sis through evolutionary relationships (PANTHER) classiﬁcation
system [27].
Two-dimensional electrophoresis-based proteomic analysis and
protein identiﬁcation
Differences in protein expression between rat hearts exposed to
Con conditions, IPC, and IR were investigated by two-dimensional
electrophoresis (2DE). Proteins of interest were identiﬁed by
matrix-associated laser desorption ionization time of ﬂight mass
spectrometry (MALDI-TOF-MS) analysis. These methods have been
described previously [19] (see Supplementary Materials for full
details of the methods).
Real time PCR
For verifying our EST results, we  randomly selected 3 differ-
entially expressed genes for analysis of quantitative expression
changes using real time PCR. For real time PCR of cytochrome
b (MT-CYB, AC 000022; forward 5′-cgaaaatctcaccccctatt-3′ and
reverse 5′- agtttacgtctcggcagatg-3′), NADH dehydrogenase subunit
4 (MT-ND4L; AC 000022.2; forward 5′-aggcccttccatattttgac-3′ and
reverse 5′-tccctttcttcaaacatcca-3′), and cytochrome c oxidase sub-
unit III (MT-CO3, AC 000022.2; forward 5′-acaggagccctatcagctct-3′
and reverse 5′-aaaatccggcaaagaagaat-3′) mRNA, total RNA was
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Fig. 1. Results of eukaryotic cluster of orthologous groups (KOG) analysis of rat heart ischemia EST sequences. (A) KOG results for intergroup comparisons between hearts
exposed  to control conditions (Con), ischemic preconditioning (IPC), and ischemia–reperfusion (IR). (B) Distribution of KOG changes for each group.
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Table  1
List of cardiac IR downregulated genes and effectiveness of IPC treatment.
Gene ID Con IPC IR Annotation IPC effect
Energy production and conversion
AP 004898.1 103.0 101.8 68.6 Cytochrome c oxidase subunit III E
YP 665632.1 42.0 54.0 26.0 Cytochrome c oxidase subunit II E
ABG11762.1 24.0 18.7 15.6 Cytochrome b E
ABG11769.1 25.0 13.5 12.5 NADH dehydrogenase subunit 4 E
AAH59124.1 7.0 2.1 4.2 Malate dehydrogenase 1, NAD (soluble) NE
CAD21559.1 4.0 5.2 2.1 NADH dehydrogenase subunit 1 E
NP  955417.1 5.0 3.1 3.1 Dihydrolipoamide dehydrogenase NE
AP 004900.1 5.0 4.2 2.1 NADH dehydrogenase subunit 4L E
NP  112413.2 5.0 5.2 1.0 Malate dehydrogenase, mitochondrial E
NP 031834.1 6.0 2.1 2.1 Cytochrome c, somatic NE
NP  036727.1 4.0 3.1 1.0 l-Lactate dehydrogenase B E
P10817 4.0 2.1 1.0 Cytochrome c oxidase subunit 6A2, mitochondrial E
NP  001007621.1 3.0 2.1 1.0 Pyruvate dehydrogenase (lipoamide) beta E
NP 058721.1 2.0 2.1 1.0 l-Lactate dehydrogenase A E
AAS75815.1 4.0 1.0 0.0 Mitochondrial aldehyde dehydrogenase precursor E
ABG11820.1 3.0 1.0 0.0 NADH dehydrogenase subunit 3 E
XP 001071017.1 1.0 2.1 0.0 ATP synthase, H+ transporting, mitochondrial F0 complex,
subunit f, isoform 2
NE
NP 075581.1 2.0 0.0 1.0 ATP synthase, H+ transporting, mitochondrial F1 complex,
alpha subunit 1, cardiac muscle
NE
AAH19156.1 2.0 0.0 1.0 Solute carrier family 25 (mitochondrial carrier, phosphate
carrier), member 26
NE
NP  001094009 2.0 1.0 0.0 Succinate dehydrogenase Ip subunit E
ABG11772.1 4.0 0.0 1.0 NADH dehydrogenase subunit 6 NE
NP  001004250.1 2.0 2.1 0.0 Ubiquinol–cytochrome c reductase core protein I E
NP 001011907.1 9.0 1.0 4.2 NADH dehydrogenase (ubiquinone) Fe-S protein 2 NE
Cytoskeleton
P68035 21.0 15.5 7.2 Actin, alpha cardiac muscle 1 E
NP 058935.2 5.0 5.2 2.1 Myosin, heavy polypeptide 6, cardiac muscle, alpha E
NP  001099960 2.0 2.1 1.0 Myosin-binding protein C, cardiac-type (Cardiac MyBP-C)
(C-protein, cardiac muscle isoform)
E
NP 001004080.1 3.0 0.0 1.0 Gelsolin NE
NP 001102452 3.0 1.0 0.0 Coﬁlin-2 (Coﬁlin, muscle isoform) E
NP  034989.1 3.0 1.0 0.0 Myosin, light polypeptide 3 E
NP  006073.2 1.0 2.1 0.0 Tubulin, alpha, ubiquitous isoform 21 NE
Signal  transduction mechanisms
NP 113865.1 2.0 6.2 0.0 Four and a half LIM domains 2 NE
NP 033419.1 3.0 4.2 1.0 Troponin C, cardiac/slow skeletal E
NP  001005908.1 2.0 1.0 1.0 Growth hormone inducible transmembrane protein NE
NP  861434.1 3.0 0.0 1.0 TNNI3 interacting kinase, Serine/threonine-protein kinase NE
NP  476485.1 2.0 0.0 1.0 Cysteine and glycine-rich protein 3 NE
NP  062244.1 2.0 0.0 1.0 Hypoxia-inducible factor prolyl hydroxylase
3-MITOCHONDRIAL
NE
XP  216433.4 2.0 0.0 1.0 RIKEN cDNA 3110001D03 NE
Lipid  transport and metabolism
NP 446126.1 5.0 7.3 3.1 Phytanoyl-CoA 2-hydroxylase NE
NP  569117.1 5.0 2.1 3.1 Acetyl-coenzyme A acyltransferase 2 NE
AAH87036.1 2.0 1.0 1.0 Acyl-coenzyme A dehydrogenase, very long chain NE
NP  077076.1 3.0 1.0 0.0 Fatty acid binding protein 3, muscle and heart E
NP  001011969.1 2.0 0.0 1.0 Serine/threonine kinase receptor associated protein NE
AAH31435.1 3.0 0.0 0.0 Chpt1 protein NE
General function prediction only
NP 036730.1 5.0 4.2 3.1 Lipoprotein lipase E
XP  922484.2 1.0 4.2 0.0 Thrombospondin 1 NE
NP  071968.1 1.0 2.1 0.0 CD151 molecule (Raph blood group) NE
NP  036644.1 2.0 0.0 1.0 Beta-2-microglobulin NE
NP  001009686.1 3.0 0.0 0.0 WD repeat domain 23 NE
Posttranslational modiﬁcation, protein turnover, chaperones
P25236 2.0 2.1 1.0 Selenoprotein P E
NP  037118.1 2.0 3.1 0.0 E3 ubiquitin-protein ligase NEDD4 E
AAH98673.1 2.0 1.0 1.0 LOC361985 protein NE
XP  343671.3 3.0 0.0 0.0 UBX domain containing 1 NE
Function unknown
NP 001007009.1 2.0 1.0 1.0 Coiled-coil-helix-coiled-coil-helix domain containing 10 NE
XP 215468.3 1.0 2.1 0.0 Mitochondrial ribosomal protein S36 NE
Inorganic ion transport and metabolism
AAH61780.1 4.0 3.1 2.1 Voltage-dependent anion channel 3 E
NP  080665.1 1.0 4.2 0.0 Polymerase delta interacting protein 38 NE
Carbohydrate transport and metabolism
NP 058704.1 13.0 12.5 5.2 Glyceraldehyde-3-phosphate dehydrogenase E
NP 997475.1 2.0 2.1 1.0 Glucose phosphate isomerase E
Extracellular structures
XP 215375.4 1.0 2.1 0.0 Collagen alpha-1(VI) chain precursor NE
Intracellular trafﬁcking, secretion, and vesicular transport
AAC06290.1 2.0 0.0 1.0 Lipocortin V NE
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Table  1 (Continued)
Gene ID Con IPC IR Annotation IPC effect
Coenzyme transport and metabolism
AAH07576.2 2.0 0.0 1.0 Putative adenosylhomocysteinase 2 NE
Nucleotide transport and metabolism
NP 036715.1 2.0 1.0 0.0 Hypoxanthine phosphoribosyltransferase 1 E
Amino acid transport and metabolism
AAL90860.1 2.0 1.0 1.0 Csr1 NE
Cell  cycle control, cell division, chromosome partitioning
AAH61872.1 2.0 0.0 1.0 Desmin NE
H
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NP 114004.1 3.0 1.0 0.0 
R, ischemia–reperfusion; IPC, ischemic preconditioning; E, effective; NE, non-effec
xtracted from rat heart tissue using the RNeasy plus Mini kit (QIA-
EN, Valencia, CA, USA) following the manufacturer’s instructions.
T reactions were performed with the iScriptTM cDNA Synthe-
is Kit for RT-PCR (Fermentas, Burlington, Ontario, Canada) using
 g of fractionated cellular RNA, which was puriﬁed as described
bove, as a template. Real-time PCR was carried out using SYBR Pre-
ix  Ex Taq (Takara, Japan). Reactions were prepared following the
anufacturer’s protocol. All reactions were carried out in triplicate
Bio-RAD, Hercules, CA, USA). Speciﬁc primers were used to detect
he presence of each of the mRNAs. Standard thermal cycling con-
itions included a hot start of 2 min  at 50 ◦C and 10 min  at 95 ◦C. The
NA was ampliﬁed through 50 cycles of 15 s at 95 ◦C, 30 s at 58 ◦C,
nd 30 s at 72 ◦C for cytochrome b, NDUFS2, actin, and tropomyosin
lpha-1 chain gene respectively. Data analysis was carried out using
io-rad software (iCycler iQTM) and Microsoft Excel. Expression
alues are presented relative to the measurements for beta-tubulin
alues in the corresponding samples.
tatistical tests
Real-time PCR and proteomics experiments were done in tripli-
ate, and the results were expressed as mean ± SEM and analyzed
sing Student’s t-test. Statistical signiﬁcance was set at *p < 0.05 vs.
on, #p < 0.05 vs. IPC.
esults
haracterization of ESTs
Three cDNA libraries were successfully generated from six rat
eart tissue samples. A total of 1714, 1694, and 1715 sequences
ere acquired from the Con, IPC, and IR groups, respectively. BLAST
nnotation of the ESTs showed that 4109 ESTs (1402, 1356, and
351 in the Con, IPC, and IR groups, respectively) had signiﬁcant
its to the 591, 559, and 615 NCBI non-redundant gene databases,
espectively (E-value ≤ e−10) (Supplementary Table 1).
unctional cluster annotation of ESTs
Functional annotation of ESTs was performed through BLAST
earches against the KOG sequence database. Of a total of 4109
STs, 1261 (89.9%), 1206 (88.9%), and 1177 (87.1%) ESTs in the
on, IPC, and IR groups, respectively, were successfully annotated
nto 25 functional KOG categories. The largest population of genes
dentiﬁed from each group was included in the category “energy
roduction and conversion” (coded as C). This population contained
82 (54.08% of total), 650 (53.9%), and 581 (49.36%) genes from the
on, IPC, and IR groups, respectively. The category “cytoskeleton”
coded as Z) contained the second largest number of genes (97, 98,
nd 96 genes from the Con, IPC, and IR groups, respectively). Addi-
ional major categories for each group are shown in Fig. 1A and B.istone-binding protein E
Expression analysis of individual genes
After functional cluster analysis, we  compared the expression
level of each identiﬁed gene based on the number of counts for each
treatment. A total of 126 genes were selected base on a fold-change
of >1.5 after IR treatment. Of these, 62 were upregulated and 64
were downregulated. The KOG functional category for each gene
was annotated (Tables 1 and 2). In the upregulated gene group, the
categories containing the largest numbers of genes were C (16.4%)
and Z (16.4%) (Fig. 2A). The categories in the downregulated gene
group containing the largest numbers of genes were C (34.3%),
Z (10%), and “lipid transport and metabolism” (8.6%, coded as I)
(Fig. 2B).
Subsequently, up- and downregulated genes were re-
categorized into “IPC-effective” and “IPC-ineffective groups”
to identify potential target genes for IPC treatment that achieve
cardioprotection during IR. Genes whose expression was  >1.5-
fold different between the IR and Con groups and for which the
IR-induced change in expression was reduced by IPC treatment
were considered IPC-effective genes. For example, the most
frequently detected gene in the upregulated group was myosin
light chain 3, with a total of 37 counts (9, 12, and 16 for the
Con, IPC, and IR groups, respectively). Expression of the myosin
light chain 3 gene was 1.77-fold higher in the IR group and only
1.33-fold higher in the IPC group. In the downregulated group, the
most frequently detected gene was  cytochrome c oxidase (COX)
subunit 3, with a total of 267 counts (103, 98, and 66 in the Con,
IPC, and IR groups, respectively). There was  a 1.56-fold change
in the expression of COX subunit 3 in the IR group, but only a
1.05 fold-change in the IPC group. In total, we identiﬁed 32 and
29 IPC-effective genes in the down- and upregulated groups,
respectively (Tables 1 and 2).
Subcellular localization analysis of encoded proteins revealed
that the mitochondrion is a major target organelle in IR injury
(Fig. 3A) and IPC treatment (Fig. 3B). Moreover, functional classiﬁca-
tion of IPC-effective mitochondrion protein-coding genes revealed
that the respiratory electron transport chain in mitochondria is
the major target of the IPC-induced cardioprotective mechanism
(Table 3).
Functional associations of ESTs
A total of 183 non-redundantly selected genes (those detected
more than three times in all groups), comprising 61 upregulated
genes, 70 downregulated genes, and 50 constantly expressed genes,
were queried to analyze functional network clusters. A functional
association network with 512 interactions between 120 genes was
constructed. A total of 26 genes had no direct interactions with
other queried genes (Fig. 4A). In the network, genes implicated in
the same function were located at short distances from each other
and formed four major functional modules: electron transport
chain/oxidative phosphorylation (23 members: 14 downregulated,
7 upregulated, and 2 constantly expressed); tricarboxylic acid (TCA)
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Table  2
List of cardiac IR upregulated genes and effectiveness of IPC treatment.
Gene ID Con IPC IR Annotation IPC effect
Energy production and conversion
NP 077374.2 6.0 6.2 9.3 Aconitase 2, mitochondrial E
NP 001005550.1 2.0 3.1 4.2 NADH dehydrogenase (ubiquinone) Fe–S protein 1, 75 kDa E
NP  569112.1 2.0 1.0 3.1 Succinate dehydrogenase complex, subunit A, ﬂavoprotein
(Fp)
E
NP 059007.1 0.0 2.1 2.1 ATP synthase, H+ transporting, mitochondrial F0 complex,
subunit c, isoform 1
NE
NP  942037.2 0.0 3.1 1.0 Electron-transferring-ﬂavoprotein dehydrogenase NE
NP 112287.1 0.0 1.0 2.1 Dihydrolipoamide S-acetyltransferase (E2 component of
pyruvate dehydrogenase complex)
E
AP  004896.1 0.0 2.1 1.0 ATP synthase F0 subunit 8 NE
NP  001178661 0.0 3.1 0.0 Cytochrome c-type heme lyase (CCHL) (holocytochrome
c-type synthase)
NE
NP 001099830 0.0 2.1 1.0 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8 NE
NP 001020317.1 0.0 0.0 3.1 NADH dehydrogenase (ubiquinone) Fe–S protein 4 E
Cytoskeleton
P04692 6.0 20.8 11.5 Tropomyosin alpha-1 chain NE
NP 036738.1 9.0 12.0 16.0 Myosin, light chain 3, alkali; ventricular, skeletal, slow E
AAA42294.1 8.0 9.3 12.4 Troponin I E
NP 035782.3 2.0 1.0 3.1 Titin isoform N2-A E
NP  001162612 1.0 2.1 2.1 Myomesin 2 NE
NP  036810.1 0.0 2.1 2.1 Tropomyosin 4 NE
NP  631977.1 0.0 3.1 1.0 Nexilin (F actin binding protein) isoform b NE
NP  074058.2 0.0 1.0 2.1 Microtubule-associated protein 1 light chain 3 beta E
XP 848839.1 0.0 1.0 2.1 Myosin regulatory light chain 2, nonsarcomeric (Myosin
RLC) isoform 1
E
General function prediction only
XP 001081394.1 0.0 4.2 2.1 Telethonin (Titin cap protein) NE
NP  001100565.1 0.0 3.1 2.1 Nuclear factor of kappa light polypeptide gene enhancer in
B-cells inhibitor, zeta
NE
Q8R560 1.0 2.1 2.1 Ankyrin repeat domain-containing protein 1 NE
NP 001099190.2 0.0 3.1 1.0 Nuclear factor of kappa light chain gene enhancer in
B-cells inhibitor, alpha [Rattus norvegicus]
NE
AAH60583.1 1.0 1.0 2.1 Cd81 protein E
NP  476484.1 1.0 0.0 2.1 Parkinson disease protein 7 E
Posttranslational modiﬁcation, protein turnover, chaperones
NP 037067.1 4.0 7.3 8.3 Crystallin, alpha B E
EDL75730.1 1.0 2.1 5.2 Complement component 7 precursor E
NP 001034090.1 2.0 1.0 3.1 TNF receptor-associated protein 1, HSP75 E
NP  001030167 1.0 2.1 2.1 RING ﬁnger protein 14 (androgen receptor-associated
protein 54) (Triad2 protein)
E
AAH06722.1 0.0 1.0 2.1 Heat shock protein 8 E
NP  037215.1 0.0 2.1 1.0 Heat shock protein 5 NE
Signal  transduction mechanisms
NP 001121052 3.0 1.0 5.2 3-Oxoacid CoA transferase 1 E
NP 113749.2 0.0 1.0 4.2 Cd36 antigen E
NP  071946.1 0.0 2.1 3.1 Cysteine-rich protein 2 E
NP  001013949.1 2.0 0.0 3.1 Phospholipase B-like 1 precursor NE
NP  001013072.1 0.0 2.1 1.0 ADP-ribosylhydrolase like 1 NE
Lipid  transport and metabolism
NP 598302.1 3.0 1.0 6.2 Mitochondrial trifunctional protein, beta subunit E
NP  445872.1 0.0 2.1 3.1 BCL2/adenovirus E1B 19 kDa-interacting protein 3 E
NP  058682 1.0 1.0 3.1 Medium-chain acyl-CoA dehydrogenase E
NP 001006967.1 0.0 0.0 3.1 Peroxisomal D3,D2-enoyl-CoA isomerase E
Q62651 1.0 0.0 2.1 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase,
mitochondrial; Flags: Precursor
E
Chromatin structure and dynamics
NP 001100058.1 0.0 0.0 3.1 Coiled-coil-helix-coiled-coil-helix domain containing 3 E
AAH49523.1 0.0 1.0 2.1 H2afvl protein E
XP  001071565 1.0 0.0 2.1 Histone H1.2 (H1 VAR.1) (H1c) E
NP  002097 1.0 0.0 2.1 Histone h2a.z E
Translation, ribosomal structure and biogenesis
CAA33199.1 4.0 5.2 11.4 60S acidic ribosomal protein P0 E
AAH29688.1 0.0 0.0 3.1 Csde1 protein E
NP  001162617 0.0 3.1 0.0 40S ribosomal protein S16 NE
Carbohydrate transport and metabolism
NP 075211.2 1.0 4.2 5.2 Triosephosphate isomerase 1 E
NP  036770.1 2.0 0.0 3.1 Glycogen phosphorylase, muscle form
(Myophosphorylase)
NE
NP  445743.2 1.0 0.0 2.1 Phosphoglycerate kinase 1 E
Intracellular trafﬁcking, secretion, and vesicular transport
NP 444180.2 0.0 3.1 6.2 Clusterin E
NP  001011918.1 1.0 0.0 2.1 Annexin A11 E
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Table  2 (Continued)
Gene ID Con IPC IR Annotation IPC effect
Function unknown
NP 001099939 3.0 2.1 8.3 Myozenin 2 E
NP 001101793.1 0.0 0.0 3.1 Ser/Thr-rich protein T10 in DGCR region E
Amino acid transport and metabolism
NP 112319.2 1.0 4.2 4.2 Aldehyde dehydrogenase family 6, subfamily A1 E
P13221.3 0.0 1.0 2.1 Aspartate transaminase (EC 2.6.1.1) (clone 8C7) – human E
Extracellular structures
NP 036788.1 1.0 2.1 3.1 Secreted protein, acidic, cysteine-rich (osteonectin) E
Inorganic ion transport and metabolism
AAH78892.1 4.0 13.5 14.6 Ferritin – Fth1 protein E
Cell  motility
P62329 1.0 0.0 2.1 Thymosin beta-4 precursor – rat (fragment) E
Cell  cycle control, cell division, chromosome partitioning
NP 037238.1 1.0 2.1 2.1 Guanine nucleotide binding protein (G protein), alpha
inhibiting 3
E
RNA processing and modiﬁcation
EAW62676 1.0 0.0 2.1 Heterogenous nuclear ribonucleoprotein K isoform 10 E
Con, control; IR, ischemia–reperfusion; IPC, ischemic preconditioning; E, effective; NE, non-effective.
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Fig. 2. Eukaryotic cluster of orthologous groups (KOG) annotation of cardiac genes whose expression was altered by ischemia–reperfusion (IR). Numbers of genes that were
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g erence
t
c
1
l
upregulated (A) and downregulated (B) by IR treatment in each KOG category are sh
ene  expression in the control (Con), IR, and IPC groups. Groups for which the diff
he  Con and IPC groups were considered to be IPC-effective.ycle/glucose metabolism/amino acid metabolism (17 members:
0 downregulated, 4 upregulated, and 3 constantly expressed); cel-
ular structure and contraction (23 members: 7 downregulated, 11
pregulated, and 5 constantly expressed); and gene transcription, The effectiveness of ischemic preconditioning (IPC) was determined by comparing
 in gene expression between the Con and IR groups was larger than that betweentranslation, and protein folding (11 members: 3 downregulated,
6 upregulat ed, and 2 constantly expressed). Biological processes
for each modiﬁed gene were identiﬁed using the PANTHER pro-
gram and were used to construct a gene-to-biological process
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Fig. 3. Subcellular localization of the proteins encoded by identiﬁed genes. (A) Subcellular localization of proteins encoded by genes whose expression was altered by
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n changes in the expression of cardiac genes following IR treat-
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ene-to-gene, gene-to-function, and function-to-function relation-
hips (Fig. 4B).
eriﬁcation of EST results by using real time-PCR
The expression patterns of three IPC effective mitochondrial
enes were veriﬁed by real-time PCR. The expression of MT-ND4L,
T-CYB, and MT-CO3 were downregulated by IR and effectively
ttenuated by IPC in both real-time PCR (Fig. 5) and EST result
Table 3).
roteomic analysis
To complement the EST-based genomic analysis, 2DE-based
roteomic analysis was performed to analyze the wide and
ynamic IR and IPC mechanisms. We  identiﬁed 14 proteins whose
xpression was different in the IR and Con groups (Fig. 6 and
upplementary Table 2). Notably, cytoskeletal proteins including
yosin, myosin regulatory light chain, tropomyosin, alpha-actin,
yomesin-1, myomesin 2, and myosin-binding protein C were
pregulated in the IR group, paralleling similar changes detected
n the EST analysis (Fig. 6).
iscussion
In the present study, we used ESTs, 2DE proteomics, and sys-
emic analysis tools to identify IPC target genes and proteins.
omparative analysis of ESTs provided not only general proﬁling
f changes in the expression of genes in rat hearts exposed to IR
r IPC, but also IPC effect-associated genes that could be effective
argets for cardioprotective therapies.
Robust regulation of energy production and consumption and
tructural integrity are essential for maintaining the function of
he heart, which continuously provides blood to the whole body.
alf of all cardiac genes function in energy production and con-
ersion, with the second largest proportion playing a role in theeconditioning (IPC)-effective genes.
cytoskeleton (Fig. 1). Any serious transcriptomic/proteomic pertur-
bation of these two major categories leads to critical heart failure
[28,29]. Our results demonstrate that IR damage causes extensive
transcriptomic perturbation in both categories. The large propor-
tion of IPC-effective genes in the C and Z categories further suggests
that the cardioprotective effect of IPC is mediated via these two
functional categories (Fig. 2A and B). In the energy metabolism
category, the mitochondrion is the major target organelle for IR
and IPC (Fig. 3). About 40% of IR- and IPC-implicated genes encode
mitochondrial proteins. Notably, the predominant IR and IPC tar-
get genes were the genes encoding components of mitochondrial
complex IV in oxidative phosphorylation complexes. COX com-
plex or complex IV is a large transmembrane protein complex
consisting of 13 protein subunits (10 of nuclear origin, and 3
synthesized in the mitochondria) [30]. IR injury reduces COX activ-
ity and IPC maintains COX activity [31]. In this process, loss of
cytochrome c and cardiolipin leads to a decrease in COX activity
[32]. Our results further suggest that expression of at least two
mitochondrial COX subunit-encoding genes, COX II (YP 665632.1)
and COX III (AP 004898.1), was downregulated by IR and preserved
by IPC.
We observed reduced expression of genes encoding compo-
nents of the cytoskeleton (e.g. actin, myosin, myosin-binding
protein, and alpha tubulin) and increased expression of genes
encoding cytoskeleton regulatory proteins (e.g. troponin I,
tropomyosin, myosin light chain 3, and myosin regulatory light
chain 2). Similar perturbations in cytoskeletal protein expression
were detected in muscle in aged rats, in which upregulation of
cytoskeletal regulatory proteins compensated for aging-induced
disorganization of sarcomeric myoﬁbrillar proteins [33]. Troponin
I, tropomyosin, and myosin light chain 3 are important regulators
of muscle contraction and calcium sensitivity. Recovery of these
proteins during reperfusion is essential for restoring cardiac con-
traction.
The results of the proteomic analysis support the conclusion that
IR induced changes in the expression of cytoskeletal and structural
proteins in the heart. Increased expression of cytoskeletal pro-
teins including myosin light chain, myosin regulatory light chain
2, tropomyosin, and myomesin 2 in the IR group paralleled the
changes detected in the EST analysis.
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Table 3
Ischemic preconditioning effective mitochondria protein coding genes.
NCBI-GI Gene name Expression GO biological process
38512108 Voltage-dependent anion-selective channel protein 3 Down Anion transport
209915614 Succinate dehydrogenase [ubiquinone] iron–sulfur subunit, mitochondrial Down Tricarboxylic acid cycle oxidative phosphorylation respiratory electron
transport chain carbohydrate metabolic process
117884 Cytochrome b Down Oxidative phosphorylation respiratory electron transport chain
110189669 Cytochrome c oxidase subunit 3 Down Oxidative phosphorylation respiratory electron transport chain
110189718 Cytochrome c oxidase subunit 2 Down Oxidative phosphorylation respiratory electron transport chain
53850628 NADH–ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Up Respiratory electron transport chain
8392833 Medium-chain speciﬁc acyl-CoA dehydrogenase, mitochondrial Up Respiratory electron transport chain acyl-CoA metabolic process nitrogen
compound metabolic process lipid metabolic process
128726  NADH–ubiquinone oxidoreductase chain 3 Down Oxidative phosphorylation respiratory electron transport chain
68341995 NADH dehydrogenase [ubiquinone] iron–sulfur protein 4, mitochondrial Up Oxidative phosphorylation respiratory electron transport chain
110189671 NADH–ubiquinone oxidoreductase chain 4L Down Oxidative phosphorylation respiratory electron transport chain
51948476 Cytochrome b–c1 complex subunit 1, mitochondrial Down Respiratory electron transport chain protein metabolic process
16758160 Bnip3:BCL2/adenovirus E1B 19 kDa-interacting protein 3 Up Unknown
45737868 Aldehyde dehydrogenase, mitochondrial Down Carbohydrate metabolic process nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process cellular amino acid and derivative metabolic
process
128764  NADH–ubiquinone oxidoreductase chain 4 Down Oxidative phosphorylation respiratory electron transport chain
56090293 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial Down Vitamin biosynthetic process carbohydrate metabolic process cellular amino
acid and derivative metabolic process lipid metabolic process
119364626 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate
dehydrogenase complex, mitochondrial
Up Coenzyme metabolic process carbohydrate metabolic process
42476181 Malate dehydrogenase, mitochondrial Down Tricarboxylic acid cycle carbohydrate metabolic process
1352170  Cytochrome c oxidase polypeptide 6A2, mitochondrial Down Oxidative phosphorylation respiratory electron transport chain
H.K. Kim et al. / Journal of Cardiology 60 (2012) 98–110 107
Fig. 4. Interaction map showing genes identiﬁed from expressed-sequence-tags of hearts exposed to control conditions (Con), ischemic preconditioning (IPC), or
ischemia–reperfusion (IR). (A) Map  showing known interactions between identiﬁed genes, IR-induced changes in heart expression for each gene, and effectiveness of IPC for
attenuating IR-induced gene expression changes in the heart. (B) Map  showing known interactions between identiﬁed genes and their biological functions. The size of each
biological function node indicates the number of implicated genes. Key: color: ( ) expression downregulated by IR (compared to Con); ( ) expression upregulated; ( )
expression unchanged; ( ) biological function; shape: (♦) IPC-effective gene (genes for which IPC reduced the IR-induced change in expression); (©) IPC-ineffective gene.
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IR and IPC also altered gene expression of major transcrip-
ion factors such as nuclear factor of kappa light polypeptide gene
nhancer in B-cells inhibitor, zeta (NFkBIZ) and alpha (IKBA) and
arkinson disease protein 7 (PARK7). Regulation of transcription
actors, NFkB and IKB, are considered as an important therapeu-
ic target for cardiac protection [34]. Activation of IkB alpha and
lockade of following NFkB signaling is known to be a protective
echanism of IPC induced-cardiac protection [35,36]. In agree-
ent with those, we found the upregulation of nuclear factor of
appa light polypeptide gene enhancer in B-cells inhibitor, zeta
NFkBIZ) and alpha (IKBA) by IPC treatment. PARK7 is a positive
egulator of androgen receptor-dependent transcription and it
rotects neurons against oxidative stress, cell death, and stroke-
nduced damage [37]. PARK7 is also suggested as a plasma marker
or stroke [38]. However, its expressional alteration in the IR- or
PC-treated heart is unknown. Because the major cause of stroke
s brain ischemia, in this consideration, increased level of PARK7
n the IR heart may  suggest that PARK7 is implicated in ischemic
njury.Fig. 5. Veriﬁcation of expressed-sequence-tags (EST) result using real time
polymerase chain reaction. Expression patterns of randomly selected 3 genes
including NADH dehydrogenase subunit 4 (MT-ND4L), cytochrome b (MT-CYB),
and cytochrome c oxidase subunit III (MT-CO3) were matched with EST results.
Ischemic preconditioning (IPC) treatment attenuated the decrease of gene expres-
sion in ischemia–reperfusion (IR) model [n = 3 each group, *p < 0.05 vs. control (con),
#p < 0.05 vs. IPC].
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rig. 6. Relative expression changes for 14 identiﬁed proteins. Representative 
schemia–reperfusion samples (right), and expression histograms.
Besides the well-known cardiac IR-related genes, we also iden-
iﬁed two interesting IPC-effective genes, myozenin 2 and ferritin,
hose expression increased. Myozenin 2 is a novel gene in human
ypertrophic cardiomyopathy [39], and high blood and tissue fer-
itin levels are a risk factor for atherosclerosis and ischemic heartes of protein spots for control (left), ischemic preconditioning (middle), and
disease [40]. Their role in cardioprotection against IR injury remains
unclear.
In conclusion, we evaluated various IPC-effective cardiac genes
in rat hearts exposed to IR and IPC using ESTs and gene/protein
systemic analysis tools. Our well-matched gene expression and
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roteomics results suggest that EST-based studies may be an effec-
ive tool for primary screening and validation of complex biological
rocesses. Further studies are required to functionally validate the
PC-effective genes identiﬁed herein. We  identiﬁed major func-
ional pathways that were modiﬁed by IR and that were effectively
rotected against modiﬁcation by IPC. Genes or proteins that we
ave identiﬁed will be used in the development of IPC-mediated
ardioprotective therapy.
cknowledgments
This work was supported by Priority Research Centers Program
nd Basic Research Program through the National Research Foun-
ation of Korea (NRF) funded by the Ministry of Education, Science
nd Technology (ROA-2007-000-20085 and 2010-0020224).
ppendix A. Supplementary data
Supplementary data associated with this article can be found, in
he online version, at doi:10.1016/j.jjcc.2012.02.004.
eferences
[1] Shimokawa H, Yasuda S. Myocardial ischemia: current concepts and future
perspectives. J Cardiol 2008;52:67–78.
[2] Tokuyama T, Sakuma T, Motoda C, Kawase T, Takeda R, Mito S, Tamekiyo H,
Otsuka M,  Okimoto T, Toyofuku M,  Hirao H, Muraoka Y, Ueda H, Masaoka Y,
Hayashi Y. Intravenous administration of adenosine triphosphate disodium
during primary percutaneous coronary intervention attenuates the transient
rapid improvement of myocardial wall motion, not myocardial stunning,
shortly after recanalization in acute anterior myocardial infarction. J Cardiol
2009;54:289–96.
[3] Kimura K, Miura S-i, Iwata A, Sugihara M,  Arimura T, Nishikawa H, Kawa-
mura A, Saku K. Association between cardiac function and metabolic factors
including adiponectin in patients with acute myocardial infarction. J Cardiol
2009;53:65–71.
[4] Bao N, Ushikoshi H, Kobayashi H, Yasuda S, Kawamura I, Iwasa M, Yamaki
T,  Sumi S, Nagashima K, Aoyama T, Kawasaki M,  Nishigaki K, Takemura G,
Minatoguchi S. Simvastatin reduces myocardial infarct size via increased nitric
oxide production in normocholesterolemic rabbits. J Cardiol 2009;53:102–7.
[5] Murakami J, Toyama T, Adachi H, Hoshizaki H, Oshima S, Kurabayashi M.
Important factors for salvaging myocardium in patients with acute myocardial
infarction. J Cardiol 2008;52:269–75.
[6] Chien KR, Reeves JP, Buja LM,  Bonte F, Parkey RW,  Willerson JT. Phospho-
lipid alterations in canine ischemic myocardium. Temporal and topographical
correlations with Tc-99m-PPi accumulation and an in vitro sarcolemmal Ca2+
permeability defect. Circ Res 1981;48:711–9.
[7] Miyamae M,  Camacho SA, Weiner MW,  Figueredo VM.  Attenuation of postis-
chemic reperfusion injury is related to prevention of [Ca2+]m overload in rat
hearts. Am J Physiol 1996;271:H2145–53.
[8] Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of
lethal cell injury in ischemic myocardium. Circulation 1986;74:1124–36.
[9]  Tomai F, Crea F, Chiariello L, Gioffre PA. Ischemic preconditioning in humans:
models, mediators, and clinical relevance. Circulation 1999;100:559–63.
10] Murphy E, Steenbergen C. Mechanisms underlying acute protection from car-
diac  ischemia–reperfusion injury. Physiol Rev 2008;88:581–609.
11] Lafﬁn JJ, Scheetz TE, Bonaldo Mde  F, Reiter RS, Chang S, Eyestone M,  Abdulkawy
H,  Brown B, Roberts C, Tack D, Kucaba T, Lin JJ, Shefﬁeld VC, Casavant TL, Soares
MB. A comprehensive nonredundant expressed sequence tag collection for the
developing Rattus norvegicus heart. Physiol Genomics 2004;17:245–52.
12] Lamirault G, Gaborit N, Le Meur N, Chevalier C, Lande G, Demolombe S, Escande
D,  Nattel S, Léger JJ, Steenman M.  Gene expression proﬁle associated with
chronic atrial ﬁbrillation and underlying valvular heart disease in man. J Mol
Cell Cardiol 2006;40:173–84.13] Clerk A, Kemp TJ, Zoumpoulidou G, Sugden PH. Cardiac myocyte gene
expression proﬁling during H2O2-induced apoptosis. Physiol Genomics
2007;29:118–27.
14] Canatan H. The effect of cardiac ischemic preconditioning on rat left ventricular
gene expression proﬁle. Cell Biochem Funct 2008;26:179–84.
[
[iology 60 (2012) 98–110
15] Hwang DM,  Dempsey AA, Wang R-X, Rezvani M, Barrans JD, Dai KS, Wang
HY, Ma  H, Cukerman E, Liu YQ, Gu JR, Zhang JH, Tsui SK, Waye MM,  Fung
KP, et al. A genome-based resource for molecular cardiovascular medicine:
toward a compendium of cardiovascular genes. Circulation 1997;96:4146–
203.
16] Megy K, Audic S, Claverie JM.  Heart speciﬁc genes revealed by EST sampling.
Genome Biol 2002;3. PREPRINT0008.
17] Li G, Ali IS, Currie RW.  Insulin-induced myocardial protection in isolated
ischemic rat hearts requires p38 MAPK phosphorylation of Hsp27. Am J Physiol
Heart Circ Physiol 2008;294:H74–87.
18] Pantos C, Mourouzis I, Dimopoulos A, Markakis K, Panagiotou M, Xinaris C,
Tzeis S, Kokkinos AD, Cokkinos DV. Enhanced tolerance of the rat myocardium
to  ischemia and reperfusion injury early after acute myocardial infarction. Basic
Res  Cardiol 2007;102:327–33.
19] Kim N, Lee Y, Kim H, Joo H, Youm JB, Park WS,  Warda M,  Cuong DV, Han J.
Potential biomarkers for ischemic heart damage identiﬁed in mitochondrial
proteins by comparative proteomics. Proteomics 2006;6:1237–49.
20] Ewing B, Green P. Base-calling of automated sequencer traces using phred. II.
Error probabilities. Genome Res 1998;8:186–94.
21] Ewing B, Hillier L, Wendl MC,  Green P. Base-calling of automated sequencer
traces using phred. I. Accuracy assessment. Genome Res 1998;8:175–85.
22] Rice P, Longden I, Bleasby A. EMBOSS: the European Molecular Biology Open
Software Suite. Trends Genet 2000;16:276–7.
23] Pertea G, Huang X, Liang F, Antonescu V, Sultana R, Karamycheva S, Lee Y,
White J, Cheung F, Parvizi B, Tsai J, Quackenbush J. TIGR Gene Indices cluster-
ing tools (TGICL): a software system for fast clustering of large EST datasets.
Bioinformatics 2003;19:651–2.
24] Altschul SF, Gish W,  Miller W,  Myers EW,  Lipman DJ. Basic local alignment
search tool. J Mol  Biol 1990;215:403–10.
25] Smoot ME,  Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features
for  data integration and network visualization. Bioinformatics 2011;27:431–2.
26] Lu Z, Szafron D, Greiner R, Lu P, Wishart DS, Poulin B, Anvik J, Macdonell C,
Eisner R. Predicting subcellular localization of proteins using machine-learned
classiﬁers. Bioinformatics 2004;20:547–56.
27] Thomas PD, Campbell MJ,  Kejariwal A, Mi  H, Karlak B, Daverman R, Diemer
K,  Muruganujan A, Narechania A. PANTHER: a library of protein families and
subfamilies indexed by function. Genome Res 2003;13:2129–41.
28] De Sousa E, Lechêne P, Fortin D, N’Guessan Bt, Belmadani S, Bigard X, Vek-
sler V, Ventura-Clapier R. Cardiac and skeletal muscle energy metabolism in
heart failure: beneﬁcial effects of voluntary activity. Cardiovasc Res 2002;56:
260–8.
29] Hein S, Kostin S, Heling A, Maeno Y, Schaper J. The role of the cytoskeleton in
heart failure. Cardiovasc Res 2000;45:273–8.
30] Fontanesi F, Soto IC, Horn D, Barrientos A. Assembly of mitochondrial
cytochrome c-oxidase, a complicated and highly regulated cellular process. Am
J  Physiol Cell Physiol 2006;291:C1129–47.
31] Lesnefsky EJ, Tandler B, Ye J, Slabe TJ, Turkaly J, Hoppel CL. Myocardial ischemia
decreases oxidative phosphorylation through cytochrome oxidase in subsar-
colemmal mitochondria. Am J Physiol 1997;273:H1544–54.
32] Lesnefsky EJ, Chen Q, Slabe TJ, Stoll MSK, Minkler PE, Hassan MO,  Tandler
B,  Hoppel CL. Ischemia, rather than reperfusion, inhibits respiration through
cytochrome oxidase in the isolated, perfused rabbit heart: role of cardiolipin.
Am J Physiol Heart Circ Physiol 2004;287:H258–67.
33] Piec I, Listrat A, Alliot J, Chambon C, Taylor RG, Bechet D. Differential proteome
analysis of aging in rat skeletal muscle. FASEB J 2005;19:1143–5.
34] Lee J-I, Burckart GJ. Nuclear factor kappa B: important transcription factor and
therapeutic target. J Clin Pharmacol 1998;38:981–93.
35] Hung L-M, Wei  W,  Hsueh Y-J, Chu W-K, Wei  F-C. Ischemic preconditioning ame-
liorates microcirculatory disturbance through downregulation of TNF-alpha
production in a rat cremaster muscle model. J Biomed Sci 2004;11:773–80.
36] Yuan Z, Liu Y, Zhang J, Kishimoto C, Wang Y, Ma  A, Liu Z. Cardioprotective
effects of peroxisome proliferator activated receptor gamma activators on
acute myocarditis: anti-inﬂammatory actions associated with nuclear factor
kappaB blockade. Heart 2005;91:1203–8.
37] Aleyasin H, Rousseaux MWC,  Phillips M,  Kim RH, Bland RJ, Callaghan S, Slack
RS,  During MJ, Mak  TW,  Park DS. The Parkinson’s disease gene DJ-1 is also a
key regulator of stroke-induced damage. Proc Natl Acad Sci USA  2007;104:
18748–53.
38] Allard L, Burkhard PR, Lescuyer P, Burgess JA, Walter N, Hochstrasser DF,
Sanchez JC. PARK7 and nucleoside diphosphate kinase A as plasma markers
for  the early diagnosis of stroke. Clin Chem 2005;51:2043–51.39] Osio A, Tan L, Chen SN, Lombardi R, Nagueh SF, Shete S, Roberts R, Willerson JT,
Marian AJ. Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy.
Circ Res 2007;100:766–8.
40] Koster JF, Sluiter W.  Is increased tissue ferritin a risk factor for atherosclerosis
and ischaemic heart disease? Br Heart J 1995;73:208.
